Zimmer Biomet Holdings, Inc. which can be found using ticker (ZBH) have now 24 analysts in total covering the stock. The consensus rating is pointing to ‘Hold’. The target price High/Low ranges between 150 and 105 calculating the average target price we see $134.19. Given that the stocks previous close was at $132.52 and the analysts are correct then there would likely be a percentage uptick in value of 1.3%. The day 50 moving average is $126.48 while the 200 day moving average is $117.50. The total market capitalization for the company now stands at $27,771m. Company Website: https://www.zimmerbiomet.com
The potential market cap would be $28,121m based on the market consensus.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
The company has a dividend yield of 0.73% with the ex dividend date set at 28-3-2023 (DMY).
Other points of data to note are a P/E ratio of 95.92, revenue per share of 33.11 and a 3.71% return on assets.
